Therapeutic efficacy of ultra-low dose rituximab in pemphigus vulgaris

Therapeutic efficacy of ultra-low dose rituximab in pemphigus vulgaris: a pilot study - NIL

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/07/070465

Enrollment

Registered

2024-07-11

Start date

Unknown

Completion date

Unknown

Last updated

2024-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L100- Pemphigus vulgaris

Interventions

Intervention1: Rituximab plus short-term oral prednisolone: Rituximab 200mg 2 dose 2weeks apart Tapering doses of oral prednisolone starting from 0.5-1 mg/kg/day Control Intervention1: Not applicable:

Eligibility

Inclusion criteria

Inclusion criteria: Adult patients with pemphigus vulgaris

Exclusion criteria

Exclusion criteria: 1. Patients who have received rituximab in the last 1 year 2. Patients with known absolute contra-indications to corticosteroids or rituximab 3. Pregnant and lactating females

Design outcomes

Primary

Measure	Time frame
Proportion of patients with complete remission (on/off therapy) Proportion of patients with partial remission (on/off therapy) Proportion of patients with relapse Proportion of patients requiring rescue treatment Mean time to disease control Mean time to disease remission Mean time to relapse Time change to ABQOL scores Proportion of patients with B-cell depletion and repopulation at different time points Proportion of patients with treatment adverse effects Timepoint: at 6 months and 12 months	—

Measure

Time frame

Proportion of patients with complete remission (on/off therapy) Proportion of patients with partial remission (on/off therapy) Proportion of patients with relapse Proportion of patients requiring rescue treatment Mean time to disease control Mean time to disease remission Mean time to relapse Time change to ABQOL scores Proportion of patients with B-cell depletion and repopulation at different time points Proportion of patients with treatment adverse effects Timepoint: at 6 months and 12 months

—

Secondary

Measure	Time frame
NilTimepoint: Not applicable	—

Countries

India

Contacts

Public ContactVishal Gupta

All India Institute Of Medical Sciences

doctor.vishalgupta@gmail.com9871213543

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026